Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Nephros (NEPH) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Nephros (NEPH) over the last 17 years, with Q3 2025 value amounting to 6.59%.

  • Nephros' EBITDA Margin rose 7400.0% to 6.59% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.06%, marking a year-over-year increase of 149500.0%. This contributed to the annual value of 0.04% for FY2024, which is 111000.0% up from last year.
  • Per Nephros' latest filing, its EBITDA Margin stood at 6.59% for Q3 2025, which was up 7400.0% from 5.61% recorded in Q2 2025.
  • In the past 5 years, Nephros' EBITDA Margin ranged from a high of 11.61% in Q1 2025 and a low of 134.12% during Q3 2022
  • Moreover, its 5-year median value for EBITDA Margin was 12.21% (2023), whereas its average is 25.87%.
  • In the last 5 years, Nephros' EBITDA Margin plummeted by -865700bps in 2022 and then surged by 1292600bps in 2023.
  • Over the past 5 years, Nephros' EBITDA Margin (Quarter) stood at 40.73% in 2021, then rose by 11bps to 36.32% in 2022, then surged by 45bps to 20.1% in 2023, then surged by 141bps to 8.19% in 2024, then fell by -20bps to 6.59% in 2025.
  • Its EBITDA Margin stands at 6.59% for Q3 2025, versus 5.61% for Q2 2025 and 11.61% for Q1 2025.